IDEC and Mitsubishi extend psoriasis agreement

18 October 2001

IDEC Pharmaceuticals and Mitsubishi Pharma have entered into anagreement to support clinical development of their psoriasis drug IDEC-114, which has the potential selectivity to regulate immune response by binding to the co-stimulatory molecule CD80.

Under the terms of the deal, which was valued at approximately $35 million and is subject to the attainment of product development, Mitsubishi will share the costs of clinical development of the drug and will also conduct parallel trials in psoriasis in Japan. Under an existing license agreement (Marketletters passim), IDEC has granted Mitsubishi an exclusive license in Asia to develop and commercialize anti-CD80 antibody products. Mitsubishi will pay IDEC royalties on sales of these products in the former's exclusive territories in Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.